Now showing items 21-40 of 655

    • Alemtuzumab in T-cell lymphoproliferative disorders 

      Dearden, CE; Matutes, E (ELSEVIER SCIENCE BV, 2006)
      The humanized monoclonal antibody alemtuzumab binds to the CD52 antigen, a glycoprotein which is widely expressed on normal and malignant B and T lymphocytes. Recently it has been demonstrated in a number of clinical trials ...
    • Alemtuzumab in T-cell malignancies 

      Dearden, CE; Matutes, E; Catovsky, D (HUMANA PRESS INC, 2002)
      Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen, which is abundantly expressed on all normal and most malignant T-lymphocytes. We summarize the results of our experience using alemtuzumab ...
    • The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. 

      Guan, J; Tucker, ER; Wan, H; Chand, D; Danielson, LS; Ruuth, K; El Wakil, A; Witek, B; Jamin, Y; Umapathy, G; Robinson, SP; Johnson, TW; Smeal, T; Martinsson, T; Chesler, L; Palmer, RH; Hallberg, B (2016-09)
      The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in ...
    • ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. 

      Carvalho, D; Taylor, KR; Olaciregui, NG; Molinari, V; Clarke, M; Mackay, A; Ruddle, R; Henley, A; Valenti, M; Hayes, A; Brandon, ADH; Eccles, SA; Raynaud, F; Boudhar, A; Monje, M; Popov, S; Moore, AS; Mora, J; Cruz, O; Vinci, M; Brennan, PE; Bullock, AN; Carcaboso, AM; Jones, C (2019)
      Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2. Despite being an amenable drug ...
    • Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. 

      Sud, A; Chattopadhyay, S; Thomsen, H; Sundquist, K; Sundquist, J; Houlston, RS; Hemminki, K (2019-09-19)
      Estimating familial cancer risks is clinically important in being able to discriminate between individuals in the population at differing risk for malignancy. To gain insight into the familial risk for the different ...
    • Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. 

      Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; Bane, AL; Bartlett, JMS; Borgquist, S; Chang, MC; Dodson, A; Ehinger, A; Fineberg, S; Focke, CM; Gao, D; Gown, AM; Gutierrez, C; Hugh, JC; Kos, Z; Laenkholm, A-V; Mastropasqua, MG; Moriya, T; Nofech-Mozes, S; Osborne, CK; Penault-Llorca, FM; Piper, T; Sakatani, T; Salgado, R; Starczynski, J; Sugie, T; van der Vegt, B; Viale, G; Hayes, DF; McShane, LM; Dowsett, M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) (2019-08)
      AIMS: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ...
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses 

      Dowsett, M (2003-11)
      BACKGROUND: The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage ...
    • Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. 

      Conteduca, V; Wetterskog, D; Sharabiani, MTA; Grande, E; Fernandez-Perez, MP; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, MJ; Climent, MA; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, MI; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G (2017-07-01)
      Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in ...
    • Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. 

      Winfield, JM; Poillucci, G; Blackledge, MD; Collins, DJ; Shah, V; Tunariu, N; Kaiser, MF; Messiou, C (2018-04)
      OBJECTIVES: The aim of this study was to identify apparent diffusion coefficient (ADC) values for typical haemangiomas in the spine and to compare them with active malignant focal deposits. METHODS: This was a retrospective ...
    • Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. 

      Amirian, ES; Ostrom, QT; Armstrong, GN; Lai, RK; Gu, X; Jacobs, DI; Jalali, A; Claus, EB; Barnholtz-Sloan, JS; Il'yasova, D; Schildkraut, JM; Ali-Osman, F; Sadetzki, S; Jenkins, RB; Lachance, DH; Olson, SH; Bernstein, JL; Merrell, RT; Wrensch, MR; Johansen, C; Houlston, RS; Scheurer, ME; Shete, S; Amos, CI; Melin, B; Bondy, ML (2019-03)
      BACKGROUND: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the ...
    • Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. 

      Went, M; Sud, A; Law, PJ; Johnson, DC; Weinhold, N; Försti, A; van Duin, M; Mitchell, JS; Chen, B; Kuiper, R; Stephens, OW; Bertsch, U; Campo, C; Einsele, H; Gregory, WM; Henrion, M; Hillengass, J; Hoffmann, P; Jackson, GH; Lenive, O; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Langer, C; Hansson, M; Kaiser, M; Sonneveld, P; Goldschmidt, H; Hemminki, K; Nilsson, B; Morgan, GJ; Houlston, RS (2017-06-16)
    • Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. 

      Fassan, M; Vianello, L; Sacchi, D; Fanelli, GN; Munari, G; Scarpa, M; Cappellesso, R; Loupakis, F; Lanza, C; Salmaso, R; Mescoli, C; Valeri, N; Agostini, M; D'Angelo, E; Lonardi, S; Pucciarelli, S; Veronese, N; Luchini, C; Rugge, M (2018)
      Background: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC). Methods: A series of 22 ENE-positive CRCs was considered and three ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...
    • Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. 

      Woolf, DK; Li, SP; Detre, S; Liu, A; Gogbashian, A; Simcock, IC; Stirling, J; Kosmin, M; Cook, GJ; Siddique, M; Dowsett, M; Makris, A; Goh, V (2019)
      Background: Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived ...
    • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

      Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
      Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
    • Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. 

      Telomeres Mendelian Randomization Collaboration; Haycock, PC; Burgess, S; Nounu, A; Zheng, J; Okoli, GN; Bowden, J; Wade, KH; Timpson, NJ; Evans, DM; Willeit, P; Aviv, A; Gaunt, TR; Hemani, G; Mangino, M; Ellis, HP; Kurian, KM; Pooley, KA; Eeles, RA; Lee, JE; Fang, S; Chen, WV; Law, MH; Bowdler, LM; Iles, MM; Yang, Q; Worrall, BB; Markus, HS; Hung, RJ; Amos, CI; Spurdle, AB; Thompson, DJ; O'Mara, TA; Wolpin, B; Amundadottir, L; Stolzenberg-Solomon, R; Trichopoulou, A; Onland-Moret, NC; Lund, E; Duell, EJ; Canzian, F; Severi, G; Overvad, K; Gunter, MJ; Tumino, R; Svenson, U; van Rij, A; Baas, AF; Bown, MJ; Samani, NJ; van t'Hof, FNG; Tromp, G; Jones, GT; Kuivaniemi, H; Elmore, JR; Johansson, M; Mckay, J; Scelo, G; Carreras-Torres, R; Gaborieau, V; Brennan, P; Bracci, PM; Neale, RE; Olson, SH; Gallinger, S; Li, D; Petersen, GM; Risch, HA; Klein, AP; Han, J; Abnet, CC; Freedman, ND; Taylor, PR; Maris, JM; Aben, KK; Kiemeney, LA; Vermeulen, SH; Wiencke, JK; Walsh, KM; Wrensch, M; Rice, T; Turnbull, C; Litchfield, K; Paternoster, L; Standl, M; Abecasis, GR; SanGiovanni, JP; Li, Y; Mijatovic, V; Sapkota, Y; Low, S-K; Zondervan, KT; Montgomery, GW; Nyholt, DR; van Heel, DA; Hunt, K; Arking, DE; Ashar, FN; Sotoodehnia, N; Woo, D; Rosand, J; Comeau, ME; Brown, WM; Silverman, EK; Hokanson, JE; Cho, MH; Hui, J; Ferreira, MA; Thompson, PJ; Morrison, AC; Felix, JF; Smith, NL; Christiano, AM; Petukhova, L; Betz, RC; Fan, X; Zhang, X; Zhu, C; Langefeld, CD; Thompson, SD; Wang, F; Lin, X; Schwartz, DA; Fingerlin, T; Rotter, JI; Cotch, MF; Jensen, RA; Munz, M; Dommisch, H; Schaefer, AS; Han, F; Ollila, HM; Hillary, RP; Albagha, O; Ralston, SH; Zeng, C; Zheng, W; Shu, X-O; Reis, A; Uebe, S; Hüffmeier, U; Kawamura, Y; Otowa, T; Sasaki, T; Hibberd, ML; Davila, S; Xie, G; Siminovitch, K; Bei, J-X; Zeng, Y-X; Försti, A; Chen, B; Landi, S; Franke, A; Fischer, A; Ellinghaus, D; Flores, C; Noth, I; Ma, S-F; Foo, JN; Liu, J; Kim, J-W; Cox, DG; Delattre, O; Mirabeau, O; Skibola, CF; Tang, CS; Garcia-Barcelo, M; Chang, K-P; Su, W-H; Chang, Y-S; Martin, NG; Gordon, S; Wade, TD; Lee, C; Kubo, M; Cha, P-C; Nakamura, Y; Levy, D; Kimura, M; Hwang, S-J; Hunt, S; Spector, T; Soranzo, N; Manichaikul, AW; Barr, RG; Kahali, B; Speliotes, E; Yerges-Armstrong, LM; Cheng, C-Y; Jonas, JB; Wong, TY; Fogh, I; Lin, K; Powell, JF; Rice, K; Relton, CL; Martin, RM; Davey Smith, G (2017-05-01)
      Importance: The causal direction and magnitude of the association between telomere length and incidence of cancer and non-neoplastic diseases is uncertain owing to the susceptibility of observational studies to confounding ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07-01)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. 

      Büchel, G; Carstensen, A; Mak, K-Y; Roeschert, I; Leen, E; Sumara, O; Hofstetter, J; Herold, S; Kalb, J; Baluapuri, A; Poon, E; Kwok, C; Chesler, L; Maric, HM; Rickman, DS; Wolf, E; Bayliss, R; Walz, S; Eilers, M (2017-12-19)
      MYC proteins bind globally to active promoters and promote transcriptional elongation by RNA polymerase II (Pol II). To identify effector proteins that mediate this function, we performed mass spectrometry on N-MYC complexes ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM ...
    • ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele 

      Matutes, E (2012-01)
      Ataxia telangiectasia patients, with constitutional bi-allelic ATM mutations, have a marked risk of lymphoid tumors and ATM mutation carriers have a smaller risk of cancer. Sporadic ATM mutations occur in 10-20% of chronic ...